Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Alamar Biosciences, Inc.

NASDAQ: ALMR · Industrial Applications and Services · 10 alerts · CIK 2104204

Share price
$30.55Close, Nov 16
Market cap
$2.12B
Shares outstanding
69.48MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Alamar Biosciences, Inc. filings on SEC EDGAR ↗

6:03 AM ET 10-Q
Financial Results

Alamar Biosciences Q3 2026 Results: Net Loss of $13.3M, Loss Widens

Alamar Biosciences reported total revenue of $89.0 million for the nine months ended September 30, 2026, representing significant growth compared to $49.2 million in the prior year period. Despite this growth, the company incurred a net loss of $47.9 million for the period as it continues to invest heavily in research, development, and commercial expansion.

Key figure
Net loss $13.3M
4:11 PM ET 8-K
Financial Results

Alamar Biosciences Financial Results

Alamar Biosciences reported Q3 2026 revenue of $33.5 million, a 68% year-over-year increase driven by strong demand for its NULISA platform and consumables. The company raised its full-year 2026 revenue guidance to a range of $121-$123 million and announced the retirement of President Tod White effective December 31, 2026.

Term
Q3 2026

“Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time. Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale.”

Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences

“Tod has been an outstanding partner and leader during a pivotal period for Alamar. He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase. On behalf of our board and the entire team, I thank Tod for his many contributions and wish him the very best in his retirement.”

Yuling Luo, Ph.D., Founder, Chief Executive Officer, and Chair of the Company

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.